Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE:002317)
China · Delayed Price · Currency is CNY 24.33
+0.74 (3.14%)
May 20, 2026, 11:34 AM CST
SHE:002317 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 2,497 | 2,507 | 2,444 | 2,600 | 2,665 | 2,416 |
Other Revenue | 15.49 | 15.49 | 23.35 | 10.39 | 10.72 | 12.74 |
| 2,513 | 2,523 | 2,467 | 2,611 | 2,676 | 2,429 | |
Revenue Growth (YoY) | 2.12% | 2.24% | -5.48% | -2.45% | 10.17% | 28.13% |
Cost of Revenue | 1,103 | 1,112 | 1,135 | 1,081 | 941.57 | 813.75 |
Gross Profit | 1,410 | 1,411 | 1,332 | 1,529 | 1,735 | 1,615 |
Selling, General & Admin | 991.42 | 1,013 | 1,002 | 1,046 | 1,172 | 1,086 |
Research & Development | 89.74 | 91.03 | 111.2 | 127.37 | 156.59 | 136.73 |
Other Operating Expenses | 14.39 | 13.52 | 8.49 | 11.49 | 24.14 | 24.06 |
Operating Expenses | 1,103 | 1,125 | 1,125 | 1,183 | 1,354 | 1,247 |
Operating Income | 306.18 | 285.75 | 206.95 | 346.21 | 380.45 | 368.16 |
Interest Expense | -5 | -5 | -25.35 | -46.91 | -73.36 | -73.81 |
Interest & Investment Income | 24.72 | 25.44 | 43.64 | 54.14 | 73.98 | 46.75 |
Currency Exchange Gain (Loss) | 1.62 | 1.62 | -1.4 | 0 | -10.65 | -0.79 |
Other Non Operating Income (Expenses) | 9.79 | 0.84 | -1.22 | -2.28 | -2.77 | 0.81 |
EBT Excluding Unusual Items | 337.31 | 308.65 | 222.61 | 351.16 | 367.64 | 341.12 |
Impairment of Goodwill | - | - | -201.68 | - | - | - |
Gain (Loss) on Sale of Investments | -33.62 | -19.49 | -18.22 | -65.23 | -19.51 | -66.73 |
Gain (Loss) on Sale of Assets | 9.98 | 6.05 | 0.03 | 21.68 | 14.69 | -0.63 |
Asset Writedown | -18.82 | -18.79 | -299.21 | -30.56 | -2.83 | -2.22 |
Other Unusual Items | 20.17 | 20.17 | -39.41 | 6.6 | 8.3 | 37.94 |
Pretax Income | 315.02 | 296.59 | -335.88 | 283.66 | 368.3 | 309.48 |
Income Tax Expense | 31.73 | 29.88 | 38.08 | 33.76 | 52.95 | 34.81 |
Earnings From Continuing Operations | 283.28 | 266.7 | -373.96 | 249.9 | 315.35 | 274.67 |
Minority Interest in Earnings | 9.68 | 9.05 | 74.81 | 13.37 | 6.7 | 2.96 |
Net Income | 292.97 | 275.75 | -299.16 | 263.27 | 322.05 | 277.63 |
Net Income to Common | 292.97 | 275.75 | -299.16 | 263.27 | 322.05 | 277.63 |
Net Income Growth | - | - | - | -18.25% | 16.00% | - |
Shares Outstanding (Basic) | 832 | 836 | 831 | 823 | 805 | 793 |
Shares Outstanding (Diluted) | 832 | 836 | 831 | 823 | 805 | 793 |
Shares Change (YoY) | 0.98% | 0.56% | 1.00% | 2.19% | 1.50% | -1.45% |
EPS (Basic) | 0.35 | 0.33 | -0.36 | 0.32 | 0.40 | 0.35 |
EPS (Diluted) | 0.35 | 0.33 | -0.36 | 0.32 | 0.40 | 0.35 |
EPS Growth | - | - | - | -20.00% | 14.29% | - |
Free Cash Flow | 165.22 | -10.97 | 109.58 | -172.44 | -204.89 | 409 |
Free Cash Flow Per Share | 0.20 | -0.01 | 0.13 | -0.21 | -0.25 | 0.52 |
Dividend Per Share | - | 0.200 | 0.200 | 0.200 | 0.200 | 0.200 |
Gross Margin | 56.09% | 55.92% | 53.99% | 58.58% | 64.82% | 66.50% |
Operating Margin | 12.19% | 11.33% | 8.39% | 13.26% | 14.22% | 15.16% |
Profit Margin | 11.66% | 10.93% | -12.12% | 10.08% | 12.03% | 11.43% |
Free Cash Flow Margin | 6.58% | -0.43% | 4.44% | -6.61% | -7.66% | 16.84% |
EBITDA | 420.3 | 401.53 | 329.38 | 465.05 | 477.9 | 462.45 |
EBITDA Margin | 16.73% | 15.92% | 13.35% | 17.81% | 17.86% | 19.04% |
D&A For EBITDA | 114.13 | 115.79 | 122.43 | 118.84 | 97.45 | 94.29 |
EBIT | 306.18 | 285.75 | 206.95 | 346.21 | 380.45 | 368.16 |
EBIT Margin | 12.19% | 11.33% | 8.39% | 13.26% | 14.22% | 15.16% |
Effective Tax Rate | 10.07% | 10.08% | - | 11.90% | 14.38% | 11.25% |
Revenue as Reported | 2,523 | 2,523 | 2,467 | 2,611 | 2,676 | 2,429 |
Advertising Expenses | - | 46.09 | 15.4 | 5.9 | 6.39 | 6.79 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.